Brought to you by 
Merck KGAA teams up with OncoMethylome for companion cancer diagnostic
03 Jun 2013
Executive Summary
OncoMethylome Sciences SA (molecular diagnostics) has licensed Merck KGAA nonexclusive worldwide rights to an assay for use with Merck’s integrin inhibitor cilengitide, a Phase III therapeutic compound for glioblastoma multiforme (GBM), the most aggressive and malignant type of brain tumor.
Deal Industry
- In Vitro Diagnostics
- Services
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck KGAA teams up with OncoMethylome for companion cancer diagnostic
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice